Teicoplanin A2-5
(Synonyms: 替考拉宁A2-5) 目录号 : GC10269
A glycopeptide antibiotic
Cas No.:91032-38-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Teicoplanin A2-5, derived from Actinoplanes teichomyceticus, is a glycopeptide antibiotic which produces a broad spectrum of antibiotic activity against gram-positive bacteria.
Teicoplanin A2-5 is the most non-polar metabolite in the family of teicoplanins. Teicoplanin, previously referred to in the literature as teichomycin, is a mixture of five closely related components of similar polarity, designated T-A2-1, 2, 3, 4 and 5 and of one more polar component, designated T-A3. Additionally, as a glycopeptide antibiotic belonging to the same family as vancomycin, teicoplanin blocks cell wall synthesis in Bacillus subtilis, which is accompanied by an intracellular accumulation of UDP-N-acetylmuramyl-pentapetide [1]. Due to the greater antibacterial activity of teicoplanin than other agents, it has been thoroughly studied as a β-1actamase-resistant agent for the treatment of human infections caused by streptococci and staphylococci, including enterococci [2].
In vitro: Up to now, in vitro study of Teicoplanin A2-5 is still in the development stage.
In vivo: Up to now, in vivo study of Teicoplanin A2-5 is still in the development stage.
References:
[1]. Somma, S., Gastaldo, L., & Corti, A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrobial Agents and Chemotherapy. 1984; 26(6): 917-923.
[2]. Traina, G., & Bonati, M. Pharmacokinetics of teicoplanin in man after intravenous administration. Journal of Pharmacokinetics and Biopharmaceutics. 1984;12(2): 119-128.
| Cas No. | 91032-38-1 | SDF | |
| 别名 | 替考拉宁A2-5 | ||
| 化学名 | 34-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-56-O-[2-deoxy-2-[(9-methyl-1-oxodecyl)amino]-β-D-glucopyranosyl]-42-O-α-D-mannopyranosyl-ristomycin A aglycone | ||
| Canonical SMILES | CC(CCCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9O[C@]%11([H])[C@](O)([H | ||
| 分子式 | C89H99Cl2N9O33 | 分子量 | 1893.7 |
| 溶解度 | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5281 mL | 2.6403 mL | 5.2807 mL |
| 5 mM | 0.1056 mL | 0.5281 mL | 1.0561 mL |
| 10 mM | 0.0528 mL | 0.264 mL | 0.5281 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。